What If the Influenza Vaccine Did Not Offer Such Variable Protection?
| Autor: | Gail Geller, Sarah N. Cox, Sheryl S. Siegmund, Bruce Y. Lee, Sarah M. Bartsch, Angie Boyce, Jeffrey P. Kahn, Elizabeth A. Mitgang, Kelly J. O'Shea |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male Vaccination Coverage Adolescent Influenza vaccine Cost-Benefit Analysis Population 03 medical and health sciences Major Articles and Brief Reports Young Adult 0302 clinical medicine Environmental health Influenza Human Disease Transmission Infectious Immunology and Allergy Humans 030212 general & internal medicine education Child Epidemics Productivity health care economics and organizations Aged Aged 80 and over Pharmacies Potential impact education.field_of_study Models Statistical Vaccination Infant Newborn Infant Middle Aged United States 030104 developmental biology Infectious Diseases Treatment Outcome Influenza Vaccines Child Preschool Female Business Seasons Medical costs |
| Zdroj: | J Infect Dis |
| Popis: | Background The protection that an influenza vaccine offers can vary significantly from person to person due to differences in immune systems, body types, and other factors. The question, then, is what is the value of efforts to reduce this variability such as making vaccines more personalized and tailored to individuals. Methods We developed a compartment model of the United States to simulate different influenza seasons and the impact of reducing the variability in responses to the influenza vaccine across the population. Results Going from a vaccine that varied in efficacy (0–30%) to one that had a uniform 30% efficacy for everyone averted 16.0–31.2 million cases, $1.9–$3.6 billion in direct medical costs, and $16.1–$42.7 billion in productivity losses. Going from 0–50% in efficacy to just 50% for everyone averted 27.7–38.6 million cases, $3.3–$4.6 billion in direct medical costs, and $28.8–$57.4 billion in productivity losses. Going from 0–70% to 70% averted 33.6–54.1 million cases, $4.0–$6.5 billion in direct medical costs, and $44.8–$64.7 billion in productivity losses. Conclusions This study quantifies for policy makers, funders, and vaccine developers and manufacturers the potential impact of efforts to reduce variability in the protection that influenza vaccines offer (eg, developing vaccines that are more personalized to different individual factors). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|